Author: Claude (AI), from PubMed abstracts · Reviewed by: Dr Mina Abdelmseih · Reviewed: 2026-11-15 · Review due: 2027-11-15

Educational content only. Not personalised medical advice. Clinical decisions remain the responsibility of the treating clinician.

Biologics and Immunosuppression for Non-infectious Uveitis

Non-infectious uveitis (NIU) is a chronic immune-mediated inflammation that may cause irreversible visual impairment [S12]. Corticosteroids are the mainstay of treatment [S4], but long-term use causes adverse effects, so steroid-sparing therapy with antimetabolites and biologics is used [S2] [S3]. Adalimumab has the most consistent randomised evidence; the choice between agents in practice is shaped by cost and access [S8] [S12].

Key points - Methotrexate and mycophenolate mofetil are both reasonable first-line steroid-sparing antimetabolites; in the FAST trial mycophenolate was not superior to methotrexate [S3]. - Adalimumab reduces treatment failure in active and corticosteroid-controlled intermediate, posterior and panuveitis, with more adverse events than placebo in VISUAL I [S1] [S2] [S12]. - Biosimilar adalimumab or infliximab was not associated with more flares after switching, which matters where cost limits access [S8] [S9]. - Corticosteroid implants may reduce recurrence but increase cataract and raised intraocular pressure (IOP); certainty is low to moderate [S4]. - Relapse risk remains despite immunomodulatory therapy [S10].

Evidence last checked: 2026-10-17 (PubMed abstracts).

Red flags

• Infectious uveitis is a different disease. The trials here enrolled non-infectious uveitis only [S1] [S2] [S3]; their results do not apply to infectious uveitis.
• Persistent inflammation despite therapy. The estimated treatment failure rate at month 6 across trials was 37.6% [S10]; flares need review, not just more steroid.
• Steroid dependence. The Egyptian consensus recommends that maintenance prednisone should not exceed 7.5 mg daily (as reported in [S8]).
• Raised IOP and cataract after steroid implants [S4].
• Early flare after a biosimilar switch. A subset of patients flare early or have tolerability problems, so monitor closely in the months after switching [S9].

Recognise it: who needs steroid-sparing therapy

• Patients with uncontrolled inflammation risk long-term complications, and those on long-term glucocorticoids risk drug adverse effects [S2].
• The Egyptian consensus advises starting systemic immunosuppression during the steroid taper, and first-line together with steroids when there is underlying systemic disease [S8].
• The adalimumab trials enrolled adults with intermediate uveitis, posterior uveitis or panuveitis that was active despite prednisone for 2 or more weeks [S2], or inactive on 10-35 mg/day prednisone [S1].

Confirm it: measuring response

• Trials defined treatment failure as a composite of new inflammatory lesions, anterior chamber cell grade, vitreous haze grade and best-corrected visual acuity [S1] [S2].
• FAST defined success at 6 months as control of inflammation in both eyes on no more than 7.5 mg prednisone daily and no more than 2 drops of prednisolone acetate 1% (as reported in [S3]).
• Anti-adalimumab antibodies: pooled prevalence 9% and 12-month incidence 27%, higher in real-life studies than trials; not using a concomitant immunosuppressant was one associated factor [S6].

Manage it

Before acting on this section, check the national and local guidelines, product information and regulatory approvals that apply where you practise. See the medical disclaimer.

Tier A (primary care / no specialist)

• Do not start or stop systemic immunosuppression without the treating uveitis or rheumatology team; these drugs carry real adverse-event burdens [S2] [S3].
• Report new symptoms in patients on these drugs to the treating team; injection-site reactions are more common with adalimumab [S12], and liver enzyme rises occurred with methotrexate and mycophenolate [S3].

Tier B (general eye clinic)

1. Steroids first, with a plan to taper. Corticosteroids are the mainstay of treatment [S4]; start a steroid-sparing agent during the taper [S8].
2. Antimetabolites. In FAST (216 adults, centres in India, the USA, Australia, Saudi Arabia and Mexico), treatment success at 6 months was 66.7% with methotrexate 25 mg weekly vs 57.1% with mycophenolate mofetil 3 g daily (doses as reported in [S3]); the difference was not significant [S3]. In posterior uveitis or panuveitis methotrexate did better (74.4% vs 55.3%); in intermediate uveitis the trend favoured mycophenolate (33.3% vs 63.6%, not significant) [S3]. Elevated liver enzymes occurred in 13.0% and 7.4% respectively [S3].
3. Comanage with rheumatology, particularly when systemic disease is present [S8].
4. Before any biologic, screen for tuberculosis and hepatitis B according to local protocol [EIC expert opinion].

Tier C (specialist centre)

1. Adalimumab. - VISUAL I (active NIU, 217 patients): median time to treatment failure 24 vs 13 weeks; hazard ratio 0.50; more adverse events and serious adverse events (28.8 vs 13.6 per 100 person-years) [S2]. Industry funded [S2]. - VISUAL II (inactive NIU on prednisone, 226 analysed): treatment failure in 39% vs 55%, hazard ratio 0.57; adverse event rates similar between groups [S1]. Industry funded [S1]. - Trial dosing was an 80 mg loading dose then 40 mg every 2 weeks (as reported in [S1] [S2]). - Pooled: adalimumab reduced treatment failure vs placebo (risk ratio 0.67) and increased injection-site reactions (risk ratio 2.67); the mortality estimate was inconclusive [S12]. Adalimumab plus corticosteroids prolonged the relapse-free period vs corticosteroids alone (hazard ratio 0.51) [S10].
2. Tocilizumab and anakinra. In a French Bayesian RCT of 112 patients with active, refractory non-anterior NIU, the primary vitreous haze outcome at week 16 was reached in 16% with adalimumab and 14% with tocilizumab; anakinra was ineffective and its arm stopped early [S11].
3. Infliximab. Comparative safety estimates are uncertain and hypothesis-generating [S12].
4. Biosimilars. In 202 patients switched from originator TNF-α inhibitors, the flare rate ratio was 1.26 (not significant), with no change in oral steroid or non-biologic immunomodulator use; 10% reverted to the originator, mostly because of injection-site pain or injector problems [S9]. The Egyptian consensus emphasises biosimilars for their lower cost, and conventional immunosuppression is usually exhausted before biologics in that setting [S8].
5. Corticosteroid implants (fluocinolone acetonide or dexamethasone). Cochrane (2023, 4 trials, 683 participants): vs sham, recurrence may fall by 60% at 6 months (low certainty); vs standard of care, recurrence likely falls by 54% at 24 months, with little or no difference in visual acuity [S4]. Implants increased raised IOP and the 0.59 mg fluocinolone implant increased cataract progression and surgery; endophthalmitis, retinal tear and detachment were not increased [S4].

Refer when

Pitfalls

• Assuming mycophenolate is better than methotrexate; FAST did not show this [S3].
• Ignoring anti-drug antibodies when adalimumab stops working; they are common in real-life practice [S6].
• Counting a single trial's adverse event rates as the full safety picture; long-term head-to-head data are lacking [S12].
• Overlooking cost: NIU costs are highest in patients with blindness and those on advanced therapies [S7].

Evidence notes

• A WHO-commissioned review found only 3 usable uveitis guidelines and many recommendations based on expert opinion [S5].
• The two meta-analyses differ: one found no significant differences between treatments in 6-month failure or visual acuity [S10], the other found adalimumab the most consistent agent [S12].
• Economic evidence comes mostly from the USA and UK; data from other countries are lacking [S7].
• Not covered by these sources: infection screening before biologics, vaccination, pregnancy, paediatric dosing, cyclosporine, tacrolimus, JAK inhibitors, and treatment duration before tapering.

Related articles

• Uveitic Macular Oedema
• Behçet Uveitis
• Vogt-Koyanagi-Harada Disease

References

See the numbered source list below. Each marker [S#] links to its PubMed and DOI record.